Translational researchers at St. Jude are advancing pediatric cancer care by moving promising compounds from the lab to clinical trials. This process starts with identifying molecular targets for hard-to-treat childhood cancers. ow.ly/AFNa50Xo1Ez

Researchers have mapped 117 kinases capable of phosphorylating the RNA polymerase II tail, revealing modifications at previously disregarded positions beyond amino acids two and five. This discovery expands our understanding of gene transcription control.

Scientists have discovered an alternative binding pocket on the pregnane X receptor (PXR), a nuclear receptor involved in drug metabolism. This finding unlocks possibilities for drug discovery related to nuclear receptors.

New research from St. Jude offers the most comprehensive analysis of medulloblastoma treatment to date, using clinical and molecular data from nearly 900 children. The findings help address the challenge of tailoring therapy to minimize long-term side-effects.

The Bringing Chemistry to Medicine symposium at St. Jude Children’s Research Hospital continues its remarkable growth, welcoming more than 1,000 attendees from 44 countries in 2025. Over six years, the symposium has reached over 3,000 participants from 73 countries.

Understanding the foundational factors affecting health—such as genetics and environment—enables more accurate prediction and prevention of disease in children. St. Jude is advancing detection and treatment to improve outcomes and quality of life.

New research reveals how tandem duplications in the UBTF gene create an abnormal transport signal, driving a high-risk, treatment-resistant subtype of acute myeloid leukemia (UBTF-TD AML). ow.ly/aYjp50XlQmW

It's Halloween 🎃 #FlourescenceFriday! Here is a microscopic pumpkin generated by showing a cell nucleus in 🟠 with the primary cilium "stem" in 🟢! I hope everyone has a spooky 👻 day! 🔬 by @stjuderesearch.bsky.social grad student Christina Wang. 🧪

Leaders at St. Jude joined experts worldwide at #SIOP2025 in Amsterdam, presenting topics ranging from advances in high-risk medulloblastoma to the future of chemotherapy-free childhood ALL treatment.

Scientists have engineered a modified form of florfenicol that uses the drug resistance mechanisms of Mycobacterium abscessus, which causes hard-to-treat infections due to its complex antibiotic resistance system, to activate and amplify its own antibiotic effect. ow.ly/oauk50XklPT

Researchers identified 423 unique ultrarare genetic variants in a diverse cohort of ALS and HSP patients, revealing significant overlap in disease-linked genes previously thought to be distinct. ow.ly/x23Y50XjN3a

Many pediatric neurological diseases are rare and complex, affecting only a small number of children. GEMINI was created at St. Jude to meet this challenge by identifying genetic mutations and developing targeted therapies, advancing from discovery to clinical trial.

By generating single-cell gene expression data, St. Jude scientists discovered how metabolism regulates regulatory T cell activation during inflammation. Mitochondria and lysosome-associated pathways work together to control these immune “brakes.” ow.ly/ccxe50XhLtW

P. David Rogers, PharmD, PhD, and J. Paul Taylor, MD, PhD, have been elected to the @nam.edu, one of the highest honors in health and medicine. ow.ly/AjRy50Xf9AX

Andrew Kleist, MD, PhD, has been named a 2025 @statnews.com Wunderkind. The designation recognizes early-career scientists making breakthrough discoveries in health and medicine. ow.ly/JEjJ50XbWhi

Scientists have solved the first complete structures of bacterial heat shock chaperone proteins Hsp40 and Hsp70, revealing how these proteins bind and release misfolded client proteins, a process central to cellular defense against protein aggregation. ow.ly/zaM750XboJ0

St. Jude recently hosted the KIDS25 BioHackathon, an event connecting students and professionals in bioinformatics, imaging, data science, artificial intelligence and software engineering to develop solutions addressing real-world research challenges.

New findings reveal that the ASPL protein plays distinct roles in both the assembly and disassembly of stress granules—mechanisms linked to neurodegenerative diseases. ow.ly/lCP550X8H3J

St. Jude Children’s Research Hospital has been ranked among the top 10 pediatric cancer hospitals by U.S. News & World Report for the 18th year in a row. Read more: ow.ly/HNLN50X7PsR

Proud to be ranked No. 2 on the @Forbes list of Best Employers for Healthcare Professionals! At St. Jude, we invest in our team so they can focus on our lifesaving mission. ow.ly/HPal50X6mBj

The application deadline for the 2026 CCSS Ann C. Mertens Career Development Award has been extended through Monday, November 3. This is a great opportunity for early-career investigators and trainees interested in childhood cancer survivorship research. Learn more: ow.ly/GOzN50WCMpP

St. Jude researchers are advancing science by harnessing light-based technologies to explore the molecular and cellular mechanisms underlying health and disease. ow.ly/3TEI50X4nsQ

At #UNGA80, St. Jude & Uzbekistan co-hosted a landmark side event, united by Bente Mikkelsen’s leadership, 8 first ladies, WHO DG @DrTedros & ministers of health worldwide. Together, we’re advancing global health for children facing catastrophic diseases.

A novel radiotracer, [18F]fluoromannitol, is now entering a first-in-human clinical trial at St. Jude. This PET/CT imaging agent could help clinicians distinguish between disease-related inflammation and bacterial infection in patients with sickle cell disease. ow.ly/PV9u50X3PJn

We have received our third consecutive exceptional rating from the National Cancer Institute as a Comprehensive Cancer Center, the highest distinction awarded. St. Jude remains the only center of its kind devoted solely to children. Learn more: ow.ly/GPA350X3P3X

New study reveals pasteurized milk containing H5N1 influenza viral components poses minimal health risks and doesn’t alter influenza immunity. Regularly drinking contaminated pasteurized milk doesn’t increase flu susceptibility in model systems. ow.ly/stPC50X32eB

St. Jude is a proud partner in the National Cancer Institute’s Childhood Cancer Data Initiative (CCDI) Federation API, which recently celebrated its first anniversary. This Childhood Cancer Awareness Month we highlight this important contribution.

Scientists have developed a high-throughput screening approach to optimize bacterial CRISPR-associated transposons (CASTs) for genome editing in human cells. This method enabled rapid detection of CAST mutants with improved efficiency and specificity. ow.ly/Skwy50X1eus

Carlos Rodriguez-Galindo, MD, EVP and Director of St. Jude Global, is at the 80th UN General Assembly to help advance sustainable, collaborative solutions for catastrophic childhood diseases. Watch the video for more on why international partnership matters.

Scientists have identified phosphatidylserine as the trigger for LC3-associated phagocytosis (LAP), clarifying how this key cellular degradation process is initiated. This discovery opens new avenues for therapies that target LAP in cancer and autoimmune diseases. ow.ly/SuNO50X0hN8

Wishing our FANTASTIC postdoctoral fellows, Harsh Kumar, Christina Daly, Sam Hack, and Rojalin Pradhan, a great Postdoctoral Appreciation Week! Thanks for all you do for the lab and for @stjuderesearch.bsky.social! 🧪

Appreciating these 2 during Postdoc Appreciation Week @stjuderesearch.bsky.social! Esmat @esfa.bsky.social spearheading our GNAI1 studies and Dianne (new!) embarking on her #raredisease research journey with us. 🧬 🧠 🧬

St. Jude, the government of Uzbekistan, WHO and Zamin Foundation are co-hosting a 90-minute side event at UN Headquarters after UNGA to highlight how leadership, collaboration and innovation are improving health outcomes for children worldwide.

A new study shows that combining indisulam with anti-GD2 immunotherapy achieves a complete therapeutic response in preclinical neuroblastoma models, regardless of tumor cell state. This could change the outlook for high-risk patients. ow.ly/yR3i50WY7tK

During National Postdoc Appreciation Week, we celebrate the contributions of our 365 postdoctoral researchers, their dedication to advancing our mission and how St. Jude is supporting postdocs with resources, mentorship and career development opportunities.

Listen to my new lecture "Developmental mutagenesis: A unified theory of why young people develop cancer" as part of @stjude.bsky.social @stjuderesearch.bsky.social Science of Childhood Lecture Series on September 18, 2025: www.linkedin.com/events/73719...

New research shows certain mitochondrial DNA mutations occur before cancer develops and are not always random. These mutations can contribute to therapy resistance in pediatric leukemia. ow.ly/V39G50WViNa

St. Jude is hosting the Virtual Research Career, Education & Training Fair on Thursday, September 25, from 10 AM – 3 PM CT. This free event is geared towards students, trainees and professionals in biomedical research and research information technology.

The SCDSTEMM clinical trial at St. Jude hopes to advance sickle cell disease research by improving stem cell collection methods. The study aims to decrease the time and resources needed for treatment, thus making gene therapy more accessible.

The 2025 Scientific Report highlights advances in pediatric leukemia research, including improved survival for acute lymphoblastic leukemia (ALL) and new strategies for rare and treatment-resistant subtypes. ow.ly/exOA50WPVZV

During Spinal Muscular Atrophy (SMA) Awareness Month, St. Jude spotlights the work of Sam Hughes, operations manager for the Center for Experimental Neurotherapeutics. Hughes played a key role in a clinical trial exploring prenatal treatment for SMA.

The 2025 St. Jude Scientific Report highlights breakthroughs in pediatric medicine: microscopy advancing biology, precision genomics in leukemia care, predictive medicine for survivors and innovations in immunotherapy. Read more: ow.ly/tmQQ50WMRiB

Ependymoma, the third most common childhood brain tumor, has seen little therapeutic progress in 30+ years. New findings reveal how the ZFTA–RELA fusion protein drives tumor formation via condensates. ow.ly/fg4r50WMPZJ

The Career Advancement Program (CAP) fellowship at St. Jude helps early career scientists like Cameron Ogg, PhD, explore career paths outside of the lab. CAP provides immersive, hands-on training and mentorship to equip postdocs for diverse roles in academia, industry and beyond.

New research demonstrates the protein midkine’s protective role against Alzheimer’s disease, inhibiting the formation of amyloid beta assemblies which are central to disease progression. ow.ly/uX3y50WJzgw

Findings from an international clinical trial co-led by Richard Finkel, MD, reveal risdiplam, a drug used to treat spinal muscular atrophy (SMA), is safe and effective in newborns. ow.ly/PHwo50WFC12

Scientists at St. Jude created an AI-informed computational method to rapidly screen large numbers of theoretical bi-specific tandem CAR designs, improving the ability to target and treat challenging tumors. ow.ly/TfJh50WFlkJ

We are excited to kick off this season of SOCC with a milestone: our 150th lecture. Join us every Thursday, from 8/14 to 11/20, at 12 PM CT / 1 PM ET for an engaging and interactive 15-week virtual lecture series.

Ewing sarcoma is the second most common bone cancer in children. St. Jude researchers are targeting one of its critical vulnerabilities: impaired DNA repair. Learn more about targeting DNA repair with PARP inhibitors.

Shape the future of childhood cancer survivorship with the 2026 CCSS Ann C. Mertens Career Development Award. This opportunity provides early-career investigators with the tools, resources and mentorship to advance survivorship research and improve outcomes.